Completed PHASE1 INTERVENTIONAL 5-arm NCT01127464

DCVax Plus Poly ICLC in Healthy Volunteers

A Randomized, Placebo-controlled, Dose-escalating, Double-blinded Phase I Study to Evaluate the Safety and Immunogenicity of Anti-DEC-205 Monoclonal Antibody (Mab) Targeted HIV Gag p24 Vaccine (DCVax-001) With Poly ICLC (Hiltonol) as Adjuvant in HIV-uninfected Healthy Volunteers

Sponsor: Rockefeller University

Conditions HIV Infection HIV-1 Infection Healthy Volunteers

Interventions DCVax-001 Placebo Poly-ICLC

Updated 6 times since 2017 Last updated: May 7, 2014 Started: May 31, 2010 Primary completion: Nov 30, 2012 Completion: Nov 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on HIV Infection and HIV-1 Infection, this trial is completed. The trial is conducted by Rockefeller University and has accumulated 6 data snapshots since 2010. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

May 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Rockefeller University

Data source: Rockefeller University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States